Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial-Reference-Cited by-同舟云学术

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Published:2011-03 Issue:3 Volume:12 Page:236-244
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gianni Luca,Dafni Urania,Gelber Richard D,Azambuja Evandro,Muehlbauer Susanne,Goldhirsch Aron,Untch Michael,Smith Ian,Baselga José,Jackisch Christian,Cameron David,Mano Max,Pedrini José Luiz,Veronesi Andrea,Mendiola Cesar,Pluzanska Anna,Semiglazov Vladimir,Vrdoljak Eduard,Eckart Michael J,Shen Zhenzhou,Skiadopoulos George,Procter Marion,Pritchard Kathleen I,Piccart-Gebhart Martine J,Bell Richard

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. HER-2/neu signal transduction in human breast and ovarian cancer;Reese;Stem Cells,1997

3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

4. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments;Kelley;Biochemistry,1992

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 531 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Docetaxel-loaded nanoformulations delivery for breast cancer management: Challenges, recent advances, and future perspectives;Journal of Drug Delivery Science and Technology;2024-02

2. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-30

3. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial;Breast Cancer Research;2024-01-11

4. Somatic mutation: Pharmacogenomics in oncology care;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

5. How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review;Trials;2023-11-06